Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.

European journal of gastroenterology & hepatology - 1 Feb 2005

Thomopoulos Konstantinos C, Theocharis George J, Tsamantas Athanasios C, Siagris Dimitrios, Dimitropoulou Dimitra, Gogos Charalambos A, Labropoulou-Karatza Chrysoula

Abstract excerpt

OBJECTIVES: Hepatic steatosis is a common feature of chronic hepatitis C. The purpose of this study was to determine factors related to the presence of steatosis and to define the role of steatosis in the response to antiviral treatment in chronic hepatitis C patients. METHODS: We retrospectively analysed all patients with chronic hepatitis C treated in a 5 year period in our department. Patients were included in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Body Mass Index
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Liver

Share to Hepatitis C, Chronic

Share to Interferons

Share to Logistic Models

Share to Ribavirin

Share to Treatment Failure

Source

Identifiers

PMID: 15674091
DOI: 10.1097/00042737-200502000-00004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C.PMID 15674091Read ↗

Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients.Semantic proximity Read ↗

Steatosis in chronic hepatitis C: relationship to the virus and host risk factors.Semantic proximity Read ↗

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.Semantic proximity Read ↗

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.Semantic proximity Read ↗

Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.Semantic proximity Read ↗

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.Semantic proximity Read ↗

Hepatitis C and steatosis.Semantic proximity Read ↗

Hepatic steatosis and hepatitis C: Still unhappy bedfellows?Semantic proximity Read ↗

Steatosis in chronic hepatitis C: why does it really matter?Semantic proximity Read ↗

Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.Semantic proximity Read ↗

Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3.Semantic proximity Read ↗

Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.